jRCT2080224653已完成1 期
Phase I study of RO6874281 in patients with advanced solid tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, singlecenter, dose-escalation study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •ECOG Performance Status of 0 or 1
- •Histologically or cytologically documented solid tumors
- •Evaluable lesion by image
排除标准
- •Meningeal metastasis or metastasis to the central nervous system requiring treatment or accompanied by symptoms
- •History or complication of autoimmune disease
- •History of severe adverse reaction by treatment with previous cancer immunotherapy
结局指标
主要结局
-
safety pharmacokinetics other other (tolerability) Observation / inspection
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase I study of RO7187797 in patients with Multiple myeloma.Multiple myelomaJPRN-jRCT2061220045anki Toshihiro6
进行中（未招募）
不适用
Phase I study of RO7187797 in patients with Multiple myeloma.Multiple myelomajRCT2061220045Chugai Pharmaceutical Co., Ltd.6
未知
1 期
Phase I Clinical Study of RG7167 in Patients with Advanced Solid TumorsJPRN-jRCT2080221451Chugai Pharmaceutical Co., Ltd.36
招募中
不适用
A phase 1 study of TAS0728 in patients with advanced solid tumors with HER2 aberration (TAIBRAKHER study)jRCT203124023530
未知
1 期
Phase I Clinical Study of RG7304 in Patients with Advanced Solid TumorsJPRN-jRCT2080221452Chugai Pharmaceutical Co., Ltd.30